Windtree Therapeutics, Inc.
WINT Healthcare Biotechnology
In the quarter to September 2025, EPS grew 99.5% and free cash flow grew 1.12%, each against the same quarter a year earlier.
Follow WINT
Windtree Therapeutics, Inc. (WINT) Piotroski F-score
Windtree Therapeutics, Inc.'s Piotroski F-score for fiscal 2019 is 5 out of 9: 5 of nine tests of profitability, leverage and efficiency passed, up from 4 in fiscal 2018.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2019 | 5 | 1.00 |
| FY2018 | 4 | 2.00 |
| FY2017 | 2 | (2.00) |
| FY2016 | 4 | — |
How fiscal 2019’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (23.05%) | (56.63%) | Fail | 0 |
| Positive operating cash flow | (24.66m) | (15.78m) | Fail | 0 |
| Rising return on assets | (23.05%) | (56.63%) | Pass | 1 |
| Cash flow above net income | 2.81m | 18.98m | Pass | 1 |
| Falling long-term leverage | 0.16 | 0.24 | Pass | 1 |
| Rising current ratio | 3.05 | 1.24 | Pass | 1 |
| No new shares issued | 200 | 4,493,000 | Pass | 1 |
| Rising gross margin | 100.00% | 100.00% | Fail | 0 |
| Rising asset turnover | 0.00 | 0.03 | Fail | 0 |
| Piotroski F-score | Mixed | 5 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| VRAX Virax Biolabs Group Limited compare | 6 |
| WINT Windtree Therapeutics, Inc. | 5 |
| VBIO Valion Bio, Inc. compare | 3 |
| BIORQ Biora Therapeutics, Inc. compare | 2 |
| NTBLQ Notable Labs, Ltd. compare | 2 |
| MTNB Matinas Biopharma Holdings, Inc. compare | 1 |
| KAPA Kairos Pharma, Ltd. compare | — |
| ELAB PMGC Holdings Inc. compare | — |
| BPTSY Biophytis SA Sponsored ADR compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover